Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

TIII Over TI in Subjects With Myocardial Infarction

Condition:   NSTEMI - Non-ST Segment Elevation MI
Intervention:   Other: Non interventional study
Sponsor:   University of Cologne
Completed - verified February 2017

Is the Current Threshold for Diagnosis of "Abnormality", Including Non ST Elevation Myocardial Infarction, Using Raised Highly Sensitive Troponin Appropriate for a Hospital Population? The CHARIOT Study

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   University Hospital Southampton NHS Foundation Trust
Not yet recruiting - verified February 2017

Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients

Conditions:   Myocardial Infarction;   Stem Cell Transplantation;   Angioplasty, Transluminal, Percutaneous Coronary
Interventions:   Drug: Atorvastatin;   Drug: Intensive Atorvastatin;   Drug: Low dose BMMSC;   Drug: Middle dose BMMSC;   Drug: High dose BMMSC;   Drug: Transplantation
Sponsors:   Yuejin Yang;   Peking Union Medical College Hospital;   The First Hospital of Hebei Medical University;   Zunyi Medical College
Not yet recruiting - verified February 2017

Prognostic Value of Plasma DPP4 Activity in ST-elevation Myocardial Infarction Patients

Conditions:   Coronary Angiography;   Dipeptidyl Peptidase 4
Intervention:   Diagnostic Test: plasma DPP4 activity
Sponsor:   Chinese PLA General Hospital
Completed - verified February 2017

System Delay and Clinical Outcome Among Chinese Patients With AMI Treated With Reperfusion Therapy (MOODY Study)

Condition:   Coronary Heart Disease
Intervention:   Procedure: Reperfusion
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Enrolling by invitation - verified February 2017

Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention

Condition:   Non-ST Elevation Myocardial Infarction (NSTEMI)
Interventions:   Drug: Tirofiban;   Drug: Cangrelor
Sponsor:   Inova Health Care Services
Not yet recruiting - verified February 2017

Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: Colchicine;   Drug: Spironolactone;   Device: SYNERGY Bioabsorbable Polymer Drug-Eluting Stent;   Drug: Colchicine-Placebo;   Drug: Spironolactone-Placebo
Sponsors:   Population Health Research Institute;   Canadian Institutes of Health Research (CIHR);   Boston Scientific Corporation
Not yet recruiting - verified February 2017

Ferric Citrate in ESRD Pilot Project

Conditions:   End Stage Renal Disease;   Chronic Kidney Diseases
Intervention:   Drug: Ferric Citrate
Sponsors:   Sreedhar Mandayam;   Keryx Biopharmaceuticals
Recruiting - verified February 2017

Genetic Determinants of ACEI Prodrug Activation

Condition:   Healthy Volunteers
Intervention:   Drug: Enalapril
Sponsor:   University of Michigan
Recruiting - verified February 2017

Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Coronary Thrombosis
Intervention:   Diagnostic Test: Platelet Acetyl Coenzyme A Carboxylase analysis in CAD
Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Completed - verified February 2017

The British Heart Foundation SENIOR-RITA Trial

Condition:   NSTEMI - Non-ST Segment Elevation MI
Interventions:   Procedure: Coronary Angiography;   Procedure: Coronary revascularisation;   Other: Optimal Medical Therapy
Sponsors:   Newcastle-upon-Tyne Hospitals NHS Trust;   British Heart Foundation;   Newcastle University
Recruiting - verified February 2017

PCSK9 Inhibitors in the Progression of Aortic Stenosis

Condition:   Aortic Valve Stenosis
Interventions:   Drug: PCSK9 Inhibitor [EPC];   Drug: Placebos
Sponsor:   Seoul National University Hospital
Not yet recruiting - verified February 2017

Pathophysiology of Acute Pain in Patients With Sickle Cell Disease

Condition:   Sickle Cell Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified February 2, 2017

Stanford Healthy Heart Study

Condition:   Obesity
Interventions:   Behavioral: Fun First;   Behavioral: Weight Watchers
Sponsors:   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2017

SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.

Condition:   TIA
Intervention:   Other: Non-Interventional Study
Sponsors:   Andrew Penn;   Genome Canada;   Genome British Columbia;   Genome Alberta;   Heart and Stroke Foundation of Canada;   Stroke Services BC;   Bruker Daltonics;   LifeLabs
Completed - verified February 2017

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Condition:   Myocardial Infarction
Interventions:   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2017

A Pooled Analysis of the Data From Two Studies of Ammonium Succinate for Menopausal Symptoms

Condition:   Menopause Related Conditions
Interventions:   Dietary Supplement: Ammonium succinate;   Other: Placebo
Sponsor:   I.M. Sechenov First Moscow State Medical University
Not yet recruiting - verified February 2017

Heart Rate Variability as a Predictor of Ischemic Heart Disease

Condition:   Acute Coronary Syndrome
Intervention:   Other: Heart rate variability
Sponsor:   University of Iowa
Completed - verified February 2017

Alirocumab in Patients With Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Hypercholesterolemia
Interventions:   Drug: alirocumab;   Drug: placebo
Sponsors:   Virginia Commonwealth University;   Regeneron Pharmaceuticals;   Sanofi
Recruiting - verified February 2017

Heart of Virginia Healthcare

Condition:   Cardiovascular Diseases
Intervention:   Other: Quality Improvement Support
Sponsors:   Virginia Commonwealth University;   Virginia Center for Health Innovation;   Center for Health Policy Development;   George Mason University;   Health Quality Innovators
Enrolling by invitation - verified February 2017

Long Term Assessment of Post Thrombotic Syndrome : OPTIMEV Study ( SPOT )

Conditions:   Post Thrombotic Syndrome;   Venous Thromboembolism;   Cardiovascular Diseases
Interventions:   Other: Villalta phone score > or = to 5;   Other: Villalta phone score < 5
Sponsors:   Association des Médecins Vasculaires Hospitaliers;   Daiichi Sankyo Inc.;   Ministry of Health, France;   LEO Pharma;   Sanofi;   University Hospital, Grenoble
Not yet recruiting - verified February 2017

Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist

Condition:   Intracerebral Hemorrhage
Interventions:   Drug: Tranexamic acid;   Drug: Saline 0.9%
Sponsors:   University Hospital, Basel, Switzerland;   Swiss National Science Foundation
Recruiting - verified February 2017

SVS VQI TransCarotid Revascularization Surveillance Project

Condition:   Carotid Artery Disease
Interventions:   Procedure: Transcarotid artery revascularization;   Procedure: Carotid endarterectomy
Sponsor:   Society for Vascular Surgery Patient Safety Organization
Recruiting - verified July 2016

Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin

Condition:   Acute Coronary Syndrome
Interventions:   Drug: High dose Rosuvastatin;   Drug: Low dose Rosuvastatin
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified February 2017

Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon

Condition:   Hyperglycemia
Intervention:   Device: percutaneous coronary intervention
Sponsor:   Second University of Naples
Completed - verified February 2017

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL_112;   Other: Placebo
Sponsor:   CSL Behring
Recruiting - verified February 2017

The IPED (Investigation of Palpitations in the ED) Study

Conditions:   Presyncope;   Arrhythmias, Cardiac;   Tachycardia, Supraventricular;   Atrial Fibrillation
Intervention:   Device: AliveCor Heart Monitor
Sponsor:   NHS Lothian
Recruiting - verified January 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Atrial Fibrillation in Cryptogenic Stroke and TIA

Conditions:   Atrial Fibrillation;   Ischemic Stroke;   TIA
Intervention:   Device: Medtronic Reveal LINQ
Sponsors:   Oslo University Hospital;   Ostfold Hospital Trust;   Haukeland University Hospital;   Rigshospitalet, Denmark;   Bispebjerg Hospital;   St. Olavs Hospital;   The Hospital of Vestfold;   Sykehuset Telemark;   Herlev Hospital;   Nordlandssykehuset HF;   Vestre Viken Hospital Trust
Recruiting - verified February 2017

STAT-STatin and Aspirin in Trauma

Conditions:   Wounds and Injuries;   Venous Thromboembolism
Interventions:   Drug: Aspirin and Rosuvastatin;   Drug: Placebo (for Aspirin and Rosuvastatin)
Sponsor:   Denver Health and Hospital Authority
Recruiting - verified February 2017

Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Conditions:   Anemia;   Non-dialysis-dependent Chronic Kidney Disease
Interventions:   Drug: vadadustat;   Drug: darbepoetin alfa
Sponsor:   Akebia Therapeutics
Recruiting - verified February 2017

Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN

Conditions:   Heart Failure;   Iron Deficiency;   Left Ventricular Systolic Dysfunction
Intervention:   Drug: Iron (III) isomaltoside 1000
Sponsors:   University of Glasgow;   NHS Greater Glasgow and Clyde
Recruiting - verified February 2017

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Condition:   Coronary Artery Disease
Interventions:   Procedure: PRU guided CABG;   Procedure: CABG per standard of care;   Device: VerifyNow assay;   Drug: Ticagrelor
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified February 2017

Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study

Condition:   Congestive Heart Failure
Intervention:   Other: Monitoring on heart failure therapy
Sponsors:   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
Recruiting - verified February 2017

A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Interventions:   Device: Orsiro;   Device: Xience
Sponsors:   University Hospital Inselspital, Berne;   University of Lausanne Hospitals
Recruiting - verified February 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2017

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified February 2017

Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: Aegis Sentinel Ligation System
Sponsors:   Aegis Medical Innovations;   Applied Health Research Centre
Not yet recruiting - verified February 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2017

Endovascular Repair of Descending ThoracoAbdominal Aortic Pathologies Using Physician Modified Endovascular Prosthesis

Condition:   Aortic Disease
Interventions:   Procedure: Exclusion of thoracoabdominal lesion;   Device: Endovascular Device Implant
Sponsor:   Rodney A. White, M.D.
Recruiting - verified September 2016

RIGENERA 2.0 Trial

Conditions:   Anterior Myocardial Infarction;   Heart Failure
Interventions:   Drug: rhu G-CSF;   Drug: optimal standard of care;   Procedure: Myocardial Contrast Echocardiography
Sponsor:   Catholic University of the Sacred Heart
Active, not recruiting - verified February 2017

Korean Coronary Overlapping Stenting Registy

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   The Catholic University of Korea
Recruiting - verified February 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified February 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

CardiAMP™ Heart Failure Trial

Condition:   Heart Failure
Interventions:   Biological: Autologous cell therapy;   Device: CardiAMP cell therapy;   Other: Sham
Sponsor:   BioCardia, Inc.
Recruiting - verified February 2017

Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Condition:   Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke
Intervention:  
Sponsor:   Bristol-Myers Squibb
Completed - verified February 2017

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified February 2017

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified February 2017

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Conditions:   Recurrent Melanoma of the Skin;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Sargramostim
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2016

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Condition:   Myocardial Injury
Interventions:   Drug: ticagrelor;   Drug: aspirin
Sponsors:   The Cleveland Clinic;   AstraZeneca
Terminated - verified February 2017

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Two-stent vs Provisional Stenting Techniques for Patients With Complex Coronary Bifurcation Lesions

Condition:   Coronary Artery Disease
Interventions:   Procedure: Two-stenting technique;   Procedure: Simple stenting technique;   Procedure: Percutaneous Coronary Intervention
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified February 2017

Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial

Condition:   Cardiogenic Shock
Intervention:   Device: HeartMate PHP
Sponsors:   Thoratec Corporation;   St. Jude Medical
Terminated - verified February 2017

A Trial of Low-dose Adjunctive alTeplase During prIMary PCI

Condition:   Myocardial Infarction
Interventions:   Drug: Alteplase;   Other: Placebo
Sponsors:   NHS Greater Glasgow and Clyde;   University of Glasgow;   National Institute for Health Research, United Kingdom
Recruiting - verified September 2016

Program for the Identification of "Actionable" Atrial Fibrillation in the Family Practice Setting

Condition:   Atrial Fibrillation
Interventions:   Other: 30 Second Pulse Check;   Device: Watch BP Home A;   Device: HeartCheck Hand-held ECG device
Sponsors:   Population Health Research Institute;   Canadian Institutes of Health Research (CIHR)
Completed - verified February 2017

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Canadian Alliance for Healthy Hearts and Minds

Condition:   Cardiovascular Diseases
Intervention:   Other: MRI
Sponsor:   Montreal Heart Institute
Recruiting - verified February 2017

Intravascular Ultrasound Guided Drug Eluting Stent Implantation in "All-comers" Coronary Lesions

Condition:   Coronary Artery Disease
Interventions:   Procedure: Angiography;   Procedure: IVUS;   Procedure: DES implantation
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
Sponsor:   VA Office of Research and Development
Recruiting - verified February 2017

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:   Drug: Observational
Sponsor:   Boehringer Ingelheim
Completed - verified February 2017

Atrial Fibrillation Detected by Continuous ECG Monitoring

Conditions:   Atrial Fibrillation;   Stroke;   Hypertension;   Diabetes
Intervention:   Device: LOOP recorder (Medtronic LINQ device)
Sponsors:   Rigshospitalet, Denmark;   Bispebjerg Hospital;   Zealand University Hospital;   Odense University Hospital;   University of Southern Denmark;   Aalborg University
Active, not recruiting - verified February 2017

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

GLP-1 and Hypoglycemia

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion;   Other: Placebo Comparator: Saline Infusion
Sponsor:   University of Maryland
Recruiting - verified February 2017

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified February 2017

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Children's Research Institute
Recruiting - verified September 15, 2016

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

Condition:   Myocardial Infarction, Acute
Intervention:  
Sponsor:   University of Arizona
Withdrawn - verified February 2017

On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction

Condition:   Acute ST-elevation Myocardial Infarction
Intervention:   Drug: Antiplatelet Regimen Modification (aspirin or ticagrelor)
Sponsor:   Clinical Centre of Serbia
Recruiting - verified February 2017

Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.

Conditions:   Cancer;   Myocardial Infarction
Interventions:   Device: No nicotine electronic cigarette;   Other: Standard counseling
Sponsor:   European Institute of Oncology
Completed - verified December 2015

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Venous Function in Cardiovascular Disease Patients

Condition:   Myocardial Infarction
Interventions:   Behavioral: interval training day 1;   Behavioral: Moderate exercise day 2;   Behavioral: Control day 3
Sponsor:   Norwegian University of Science and Technology
Completed - verified February 2017

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents

Conditions:   Coronary Artery Disease;   Angina Pectoris;   Myocardial Infarction
Interventions:   Device: Sirolimus-eluting stent with a bioresorbable polymer (Orsiro);   Device: Everolimus-eluting stent with a durable polymer
Sponsors:   University Hospital Inselspital, Berne;   Biotronik AG;   University of Bern
Active, not recruiting - verified February 2017

Systematic Assessment of Competitive Flow in Coronary Artery Bypass Grafts by Wave Intensity Analysis

Condition:   Coronary Artery Bypass
Intervention:  
Sponsor:   Imperial College London
Recruiting - verified February 2017

International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens

Condition:   Contraception
Intervention:  
Sponsors:   Center for Epidemiology and Health Research, Germany;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Active, not recruiting - verified December 2016

A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

Conditions:   Severe, Refractory Asthma;   Airway Inflammation;   Airflow Obstruction
Intervention:   Drug: Pioglitazone
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 25, 2017

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes
Interventions:   Procedure: euinsulinemic euglycemic glucose clamp;   Procedure: euinsulinemic hyperglycemic glucose clamp;   Procedure: Hyperinsulinemic euglycemic glucose clamp;   Procedure: Hyperinsulinemic hyperglycemic glucose clamp
Sponsors:   University of Maryland;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2017

Transfemoral Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)

Condition:   Aortic Valve Stenosis
Intervention:   Device: Sapien XT™ transcatheter heart valve and delivery system
Sponsor:   Edwards Lifesciences
Completed - verified February 2017

An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Genentech, Inc.
Completed - verified February 2017

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Completed - verified February 2017

Effect of Diet on Vascular Disease in Pre-Menopausal Women

Conditions:   Cardiovascular Diseases;   Vascular Disease;   Inflammation;   Insulin;   Triglycerides
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified February 14, 2017

Heart Outcomes Prevention Evaluation-3

Conditions:   Cardiovascular Disease;   Stroke
Interventions:   Drug: Candesartan/HCT;   Drug: Rosuvastatin
Sponsor:   Population Health Research Institute
Completed - verified February 2017

Acute Chest Pain Treatment and Evaluation (ACTION) Study

Condition:   Chest Pain
Intervention:   Procedure: Stress nuclear scan
Sponsors:   Singapore General Hospital;   National Medical Research Council (NMRC), Singapore;   National Heart Centre Singapore
Completed - verified February 2017

Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

Condition:   Graft vs Host Disease
Interventions:   Drug: Topical Dexamethasone;   Drug: Placebo
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 13, 2017

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Lymphoma;   Leukemia;   Myeloproliferative Disorders;   Multiple Myleoma;   Myelodysplastic Syndrome
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Procedure: PBSC transplantation;   Genetic: T cell DLI with sirolimus generated donor TH-2 cells;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim;   Genetic: T-Rapa cell DLI
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified February 3, 2017

High-intensity Exercise Training in Patients With Post-infarction Heart Failure

Conditions:   Heart Failure;   Myocardial Infarction
Interventions:   Behavioral: Moderate intensity exercise training;   Behavioral: High intensity exercise training
Sponsor:   Norwegian University of Science and Technology
Completed - verified February 2017

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Condition:   Coronary Artery Disease
Intervention:   Drug: pexelizumab in conjunction with CABG
Sponsors:   Alexion Pharmaceuticals;   Procter and Gamble
Active, not recruiting - verified February 2017

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Conditions:   Cardio-pulmonary Bypass;   Coronary Artery Bypass Graft
Intervention:   Drug: pexelizumab
Sponsor:   Alexion Pharmaceuticals
Active, not recruiting - verified February 2017